EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticancer Potential of Diazepam: Pharmacological Relevance and Clinical Evidence

Md. Mizan, Noshin Tasnim Yana, Ali Mohamod Wasaf Hasan, Mohammed Burhan Uddin, Md Abu Sayeed, Akayed Hasan, Shafayatun Nahar Tinu, Imam Hossen Rakib, Md. Sakib Al Hasan

Journal of Phytochemical Insights · 2025

DOI: 10.71193/jpci.20250003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Phytochemical Insights, 2025. Verfasst von Md. Mizan und 8 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer treatments such as chemotherapy, radiation, and targeted therapies often face challenges like severe side effects, drug resistance, and high costs. Repurposing existing medications is a promising strategy to improve treatment outcomes. Diazepam (DZP), a benzodiazepine commonly used for anxiety, has recently shown potential anticancer effects. This study explores the anticancer activity of DZP, focusing on its mechanisms of action, pharmacological relevance, immunotherapy, pharmacokinetics profile, toxicological profile, and clinical evidence through literature review from articles and journals in PubMed, Scopus, Google Scholar, and the Web of Science. DZP exerts antitumor effects by inducing apoptosis, inhibiting cell proliferation, and modulating oxidative stress and cell cycle dynamics against various cancers: blood cancer, brain cancer, breast cancer, colorectal cancer, glioblastoma, lung cancer, and skin cancer. DZP also demonstrates synergistic potential with conventional chemotherapeutic agents, enhancing their effectiveness while reducing patient anxiety and stress. Its pharmacokinetic profile, characterized by rapid absorption, extensive tissue distribution, and a prolonged half-life, supports its utility as a sustained anticancer agent. A significant gap in our investigation is the lack of clinical data on DZP; additional clinical evidence is required to validate its anticancer potential and establish it as an anticancer drug in the near future. Its sedative and CNS depressant effects necessitate cautious use, particularly in patients with hepatic or renal impairment. This review highlights the potential of DZP as a cost-effective, repurposed therapeutic option for cancer treatment. Additionally, it demonstrates how DZP may be a viable anticancer medication with a potential mechanism, maybe providing a better safety profile and less serious side effects than traditional treatments like chemotherapy.

Zitieren

APA

Mizan, M., Yana, N. T., Hasan, A. M. W., Uddin, M. B., Sayeed, M. A., Hasan, A., Tinu, S. N., Rakib, I. H., & Hasan, M. S. A. (2025). Anticancer Potential of Diazepam: Pharmacological Relevance and Clinical Evidence. Journal of Phytochemical Insights. https://doi.org/10.71193/jpci.20250003

Vancouver

Mizan M, Yana NT, Hasan AMW, Uddin MB, Sayeed MA, Hasan A, et al. Anticancer Potential of Diazepam: Pharmacological Relevance and Clinical Evidence. Journal of Phytochemical Insights. 2025. doi:10.71193/jpci.20250003

BibTeX
@article{Mizan2025,
  author = {Mizan, Md. and Yana, Noshin Tasnim and Hasan, Ali Mohamod Wasaf and Uddin, Mohammed Burhan and Sayeed, Md Abu and Hasan, Akayed and Tinu, Shafayatun Nahar and Rakib, Imam Hossen and Hasan, Md. Sakib Al},
  title = {Anticancer Potential of Diazepam: Pharmacological Relevance and Clinical Evidence},
  journal = {Journal of Phytochemical Insights},
  year = {2025},
  doi = {10.71193/jpci.20250003}
}
Kostenlos starten →